Related Experiment Video
Updated: Apr 5, 2026
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
Published on: October 25, 2011
Clinical implications of molecular heterogeneity in triple negative breast cancer
Brian D Lehmann1, Jennifer A Pietenpol1
1Department of Biochemistry, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Preston Research Building, 2200 Pierce Avenue, Nashville, TN 37232, USA.
Abstract:
Triple negative breast cancer (TNBC) is a molecularly heterogeneous disease lacking recurrent targetable alterations and thus therapeutic advances have been challenging. The absence of ER, PR and HER2 amplifications, leaves combination chemotherapy as the standard of care treatment option in the adjuvant, neoadjuvant and metastatic settings. Recently, multiple studies have shed some light on the heterogeneity of TNBC and identified distinct transcriptional subtypes with unique biologies. Herein we review the molecular heterogeneity and the impact on previous and future clinical trials.
Insights
Triple negative breast cancer (TNBC) is a complex disease lacking targeted therapies. Understanding its molecular subtypes is crucial for improving treatment strategies and clinical trial outcomes.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Triple negative breast cancer (TNBC) presents a significant therapeutic challenge due to its molecular heterogeneity.
- The lack of Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2 amplifications necessitates reliance on combination chemotherapy.
- Recent research has begun to elucidate distinct transcriptional subtypes within TNBC, each with unique biological characteristics.
Purpose of the Study:
- To review the current understanding of molecular heterogeneity in triple negative breast cancer.
- To analyze the impact of this heterogeneity on past and future clinical trials for TNBC.
Main Methods:
- Literature review of studies investigating TNBC molecular heterogeneity.
- Analysis of transcriptional subtypes and their biological implications.
- Examination of clinical trial data in relation to TNBC subtypes.
Main Results:
- TNBC is confirmed to be a highly heterogeneous disease at the molecular level.
- Distinct transcriptional subtypes with varying biologies have been identified.
- This heterogeneity significantly impacts the design and outcomes of clinical trials.
Conclusions:
- Recognizing TNBC's molecular subtypes is essential for developing targeted therapies.
- Future clinical trials must account for this heterogeneity to improve treatment efficacy.
- Further research into TNBC subtypes will pave the way for personalized treatment approaches.
